These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 30660512)

  • 21. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
    Chang MC; Cheng HI; Hsu K; Hsu YN; Kao CW; Chang YF; Lim KH; Chen CG
    Front Immunol; 2018; 9():3152. PubMed ID: 30705677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Should vascular effects of newer treatments be addressed more completely?
    Yang EH; Watson KE; Herrmann J
    Future Oncol; 2015; 11(14):1995-8. PubMed ID: 26198824
    [No Abstract]   [Full Text] [Related]  

  • 23. The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib.
    Mulas O; Abruzzese E; Luciano L; Iurlo A; Attolico I; Castagnetti F; Galimberti S; Bonifacio M; Annunziata M; Gozzini A; Orlandi EM; Stagno F; Binotto G; Pregno P; Fozza C; Loi M; Trawinska MM; De Gregorio F; Cattaneo D; Albano F; Iezza M; Baratè C; Scaffidi L; Elena C; Giai V; Scalzulli E; Breccia M; La Nasa G; Caocci G
    Ann Hematol; 2024 Feb; 103(2):427-436. PubMed ID: 38012435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events.
    Carneiro BA; Kaplan JB; Giles FJ
    Expert Rev Hematol; 2015 Aug; 8(4):457-79. PubMed ID: 25938861
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing.
    Medeiros BC; Possick J; Fradley M
    Blood Rev; 2018 Jul; 32(4):289-299. PubMed ID: 29454474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?
    Eskazan AE; Ozmen D
    Expert Rev Hematol; 2017 Jul; 10(7):583-586. PubMed ID: 28586242
    [No Abstract]   [Full Text] [Related]  

  • 27. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
    Abbott BL
    Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system.
    Rashid N; Koh HA; Lin KJ; Stwalley B; Felber E
    J Oncol Pharm Pract; 2018 Jun; 24(4):253-263. PubMed ID: 29284347
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase.
    Rosti G; Castagnetti F; Gugliotta G; Palandri F; Baccarani M
    Crit Rev Oncol Hematol; 2012 May; 82(2):159-70. PubMed ID: 21565522
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Arterial hypertension assessment in a population with chronic myeloid leukemia.
    Roa-Chamorro R; Jaén-Águila F; Puerta-Puerta JM; Torres-Quintero L; González-Bustos P; Mediavilla-García JD
    Sci Rep; 2021 Jul; 11(1):14637. PubMed ID: 34282224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
    Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
    Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Cardiovascular Adverse Events of Long-term Treatment with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Report from the Nagasaki CML Study Group.
    Chiwata M; Itonaga H; Sato S; Hashimoto M; Fujioka M; Kasai S; Sakamoto H; Toriyama E; Nakashima J; Kamijo R; Kitanosono H; Kobayashi Y; Horai M; Taguchi M; Matsuo M; Makiyama J; Takasaki Y; Matsuo E; Horio K; Ando K; Sawayama Y; Taguchi J; Kawaguchi Y; Tsushima H; Imanishi D; Imaizumi Y; Yoshida S; Jo T; Nonaka H; Moriuchi Y; Nagai K; Yokota KI; Hata T; Miyazaki Y
    Intern Med; 2021 Jul; 60(14):2207-2216. PubMed ID: 33612681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ultrasound arterial anomalies in patients exposed to nilotinib therapy for chronic myeloid leukemia.
    Sarlon-Bartoli G; Michel Q; Sarlon E; Carcopino-Tusoli M; Suchon P; Soler R; Bartoli MA; Brunet D; Morange P; Charbonnier A
    J Med Vasc; 2021 Apr; 46(2):66-71. PubMed ID: 33752848
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML.
    Valent P; Hadzijusufovic E; Hoermann G; Füreder W; Schernthaner GH; Sperr WR; Kirchmair R; Wolf D
    Leuk Res; 2017 Aug; 59():47-54. PubMed ID: 28549238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia.
    Rea D; Mirault T; Cluzeau T; Gautier JF; Guilhot F; Dombret H; Messas E
    Haematologica; 2014 Jul; 99(7):1197-203. PubMed ID: 24658819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: A network meta-analysis.
    Fachi MM; Tonin FS; Leonart LP; Rotta I; Fernandez-Llimos F; Pontarolo R
    Br J Clin Pharmacol; 2019 Oct; 85(10):2280-2291. PubMed ID: 30907446
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib.
    Caocci G; Mulas O; Capodanno I; Bonifacio M; Annunziata M; Galimberti S; Luciano L; Tiribelli M; Martino B; Castagnetti F; Binotto G; Pregno P; Stagno F; Abruzzese E; Bocchia M; Gozzini A; Albano F; Fozza C; Luzi D; Efficace F; Simula MP; Scaffidi L; Baratè C; De Gregorio F; Stella R; Gugliotta G; Pirillo F; Trawinska MM; Sicuranza A; Cattaneo D; Attolico I; Scalzulli E; Iurlo A; Foà R; Breccia M; La Nasa G
    Ann Hematol; 2021 Aug; 100(8):2005-2014. PubMed ID: 33388860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular risk assessments in chronic myeloid leukemia allow identification of patients at high risk of cardiovascular events during treatment with nilotinib.
    Breccia M; Colafigli G; Molica M; Alimena G
    Am J Hematol; 2015 May; 90(5):E100-1. PubMed ID: 25683643
    [No Abstract]   [Full Text] [Related]  

  • 40. Predictive value of clinical examination parameters for cardiovascular adverse events during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors.
    Nakamae M; Nakamae H; Hashimoto M; Koh H; Nakashima Y; Hirose A; Hino M
    Int J Hematol; 2022 Mar; 115(3):329-335. PubMed ID: 34787835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.